Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New keyhole breast cancer surgery could offer better looks, same safety

NCT ID NCT07539545

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new type of breast-conserving surgery that uses a small camera inserted through a hidden armpit incision to remove tumors, compared to the standard open approach. About 1,366 women with early-stage breast cancer will be randomly assigned to one of the two surgeries. The goal is to see if the new method leads to fewer complications, better cosmetic results, and similar cancer control over five years.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Minimal accessory-incision-assisted endoscopic breast-conserving surgery
What this could lead to
If successful, this could offer a less invasive surgical option for breast cancer that improves cosmetic results while maintaining safety and cancer control.
What could go wrong
This is an early-stage trial comparing surgical techniques, not a new drug or cure. The procedure may not reduce recurrence risk or could have unforeseen complications. Results may not apply to all breast cancer patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 1,366 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Apr 2026

An estimate. Start dates often move.

Expected to finish

Dec 2032

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * female patients aged 18-70 years (inclusive); * preoperative pathological examination confirmed it as invasive breast cancer or ductal carcinoma in situ; * both clinical and imaging examinations clearly indicated that the lesion was a single lesion confined within the gland, without invasion of the skin, subcutaneous tissue, pectoralis major muscle, or the nipple-areola complex; * tumors in the inner and outer quadrants (three classification method, as shown in Figure 2); * preoperative tumor size ≤3 cm (pre-neoadjuvant chemotherapy if applicable); * the tumor is more than 2 cm away from the nipple (the distance is based on physical examination, with MRI and ultrasound as supplementary methods); * the patient has a clear intention to preserve the breast and can receive standard radiotherapy after the operation; * voluntary provision of informed consent. . Exclusion Criteria: * clinically or radiologically evaluated as multifocal or multicentric breast cancer, with diffuse suspicious calcification, long spiculated masses, extensive local resection unable to obtain sufficient negative margins or ideal shape; * persistent positive tumor margins, and resection cannot ensure negative margins after resection; * inflammatory breast cancer; * pregnant and lactating women; * previous history of breast cancer surgery (including patients with recurrence after ipsilateral breast-conserving surgery); * breast cancer genetic gene mutations (such as BRCA1/2 gene mutations); * preoperative severe underlying diseases that cannot tolerate general anesthesia and surgical procedures. * other situations that the researchers consider unsuitable for participation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • West China hospital of Sichuan University

    Chengdu, Sichuan, 610000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.